Overview of new approaches that aim to improve outcomes for patients with chronic lymphocytic leukemia (CLL) presented at the ESH 3^rd Translational Research Conference: Chronic Lymphocytic Leukaemia.

Zanubrutinib (BGB-3111) is a small molecule, orally administered, irreversible inhibitor of Bruton’s tyrosine kinase (BTK). Watch the mode of action (MoA) video to learn more.

Ociperlimab (BGB-A1217) is an investigational humanized monoclonal antibody designed to bind and inhibit TIGIT. Watch the MoA video to learn more.

This masterclass on gastrointestinal (GI) cancers provided clinicians with an overview of the current treatment landscape and new therapies for certain GI cancers.

Overview of current approaches for the management of patients with chronic lymphocytic leukemia (CLL) presented at the 7^th ESH Translational Research Conference on Lymphoid Malignancies.